Metofane Asp 99.99% 99.99 % Spray is a Health Canada–registered veterinary drug (DIN 02019027) held by Janssen, containing Methoxyflurane. Health Canada lists its status as Cancelled Post Market (status date 04 Aug 2004). Nexara Health has matched 20 registrations of Methoxyflurane across 15 other regulated markets.
Health Canada registration
| DIN | 02019027 |
|---|---|
| Brand name | Metofane Asp 99.99% |
| Active ingredient | Methoxyflurane |
| Strength | 99.99 % |
| Dosage form | Spray |
| Route | Inhalation |
| Company | Janssen |
| Status | Cancelled Post Market — 04 Aug 2004 |
| Class | Veterinary |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Methoxyflurane registered in other markets
20 registrations of the same molecule in 15 national registries outside Canada. Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Australia | Penthrox (Combination Pack) | Dv | Liquid for inhalation 999 mg per g, 3 mL (with inhaler) | DB | PBS | |
| Czech Republic | Penthrox | — | 99,9%,3ML | Inh Liq Vap | R | SUKL DLP |
| Denmark | Penthrox | Medical Developments NED B.V. | 99,9 %, 3 ml | væske til inhalationsdamp | Decentral procedure | Laegemiddelstyrelsen |
| Hong Kong | Penthrox Inhalation Liquid 99.9% | Link Healthcare Hong Kong Limited | Registered | DH Drug Office | ||
| Iceland | Penthrox | Medical Developments NED B.V. | 99,9 % | innö.guf | 1 | Lyfjastofnun lyfjaverdskra |
| Ireland | Methoxyflurane Medical Developments MD&P 99.9%, 3 ml inhalation vapour, liquid | Medical Developments MD&P Limited | Inhalation vapour, liquid | Not marketed | HPRA | |
| Ireland | Penthrox 99.9%, 3 ml inhalation vapour, liquid | Medical Developments MD&P Limited | Inhalation vapour, liquid | Marketed | HPRA | |
| Malta | Penthrox 99.9%, 3ml inhalation vapour, liquid | Medical Developments NED B.V. | Inhalation Vapour, Liquid | Withdrawn | Medicines Authority | |
| Norway | Penthrox væske til inh damp 99,9 % | Medical Developments NED B.V. | 3 | Væske til inhalasjonsdamp | Aktiv oppføring | FEST (DMP) |
| Poland | Penthrox | Medical Developments NED B.V. | 99,9 % | Płyn do sporządzania inhalacji parowej | 2024-05-23 | URPL RPL |
| Saudi Arabia | PENTHROX 99.9 % liquid for inhalation | — | 99.9 | Inactive | SFDA | |
| Saudi Arabia | PENTHROX 99.9 % liquid for inhalation | — | 99.9 | Inactive | SFDA | |
| Saudi Arabia | PENTHROX 99.9 % liquid for inhalation | — | 99.9 | Inactive | SFDA | |
| Singapore | Penthrox Inhalation Liquid 99.9% | Link Healthcare Singapore Pte Ltd | 99.90% | Inhalant | Prescription Only | HSA |
| South Africa | Penthrop | Equity Pharmaceuticals (Pty) Ltd | % m/m/1,0ml | Inh | S5 | DoH SEP database |
| Taiwan | Penthrane | Abbott Lab. (Abbott Pharmaceuticals Inc. Div. Of Abbott Lab.) | 鼻用吸入劑 | 已註銷 | TFDA | |
| Taiwan | Penthrane | Abbott Lab. (Abbott Pharmaceuticals Inc. Div. Of Abbott Lab.) | 鼻用吸入劑 | 已註銷 | TFDA | |
| Taiwan | Penthrox | Medical Developments International Limited | 吸入用液劑 | 已註銷 | TFDA | |
| United Arab Emirates | Penthrox Inhaler | Medical Developments International Limited , Australia, Scoresby , 3179 | 99.9% | Inhaler | Active | EDE |
| United Kingdom | Methoxyflurane 99.9% inhalation vapour liquid 3ml bottles with device | — | 0001 | NHS dm+d VMP |
See every manufacturer of Methoxyflurane worldwide →
Regulator price references for Methoxyflurane
Published list or reimbursement prices for Methoxyflurane presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.
| Country | Product | Strength | Pack | Price | Type | Source | As of |
|---|---|---|---|---|---|---|---|
| Australia | Penthrox (Combination Pack) | Liquid for inhalation 999 mg per g, 3 mL (with inhaler) | 50.00 AUD | ex-manufacturer | PBS | 2026-09-08 | |
| Iceland | Penthrox | 99.9pct | glas | 4,649.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Norway | Penthrox | 99.9pct | 3 ml, stk | 399.50 NOK | max AUP (pharmacy retail) | DMP (Statens legemiddelverk) maksimalpris | 2026-09-07 |
| Saudi Arabia | PENTHROX 99.9 % liquid for inhalation | 99.9pct | 125.00 SAR | public | SFDA | 2026-09-01 | |
| Saudi Arabia | PENTHROX 99.9 % liquid for inhalation | 99.9pct | 800.00 SAR | public | SFDA | 2026-09-01 | |
| Saudi Arabia | PENTHROX 99.9 % liquid for inhalation | 99.9pct | 1,121.50 SAR | public | SFDA | 2026-09-01 | |
| South Africa | Penthrop | 1ml | 3 | 621.40 ZAR | single exit price | DoH SEP database | 2026-09-01 |
| United Arab Emirates | Penthrox Inhaler | 99.9pct | Single Combination pack (3 mL Glass Vial + Inhaler Device + Carbon Filter/Activated Carbon Chamber) | 138.00 AED | public | EDE | 2026-08-31 |
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Metofane Asp 99.99% (DIN 02019027) marketed in Canada?
No. Health Canada lists DIN 02019027 as Cancelled Post Market as of 04 Aug 2004.
Who holds the Canadian licence for this product?
Janssen is the company of record in the Health Canada Drug Product Database.
Is Methoxyflurane registered outside Canada?
Yes — Nexara Health has matched 20 registrations in 15 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02019027, status date 2004-08-04; national medicine registries: DH Drug Office, DoH SEP database, EDE, FEST (DMP), HPRA, HSA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, SUKL DLP, TFDA, URPL RPL; price sources: DMP (Statens legemiddelverk) maksimalpris, DoH SEP database, EDE, Lyfjastofnun lyfjaverdskra, PBS, SFDA. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02019027, status date 2004-08-04; national medicine registries: DH Drug Office, DoH SEP database, EDE, FEST (DMP), HPRA, HSA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, SUKL DLP, TFDA, URPL RPL; price sources: DMP (Statens legemiddelverk) maksimalpris, DoH SEP database, EDE, Lyfjastofnun lyfjaverdskra, PBS, SFDA.
Health Canada Drug Product Database (DPD), DIN 02019027, status date 2004-08-04; national medicine registries: DH Drug Office, DoH SEP database, EDE, FEST (DMP), HPRA, HSA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, SUKL DLP, TFDA, URPL RPL; price sources: DMP (Statens legemiddelverk) maksimalpris, DoH SEP database, EDE, Lyfjastofnun lyfjaverdskra, PBS, SFDA. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.